Opportunity Information: Apply for RFA RM 14 002
Apply for RFA RM 14 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Renewal Applications for Technology Development for New Affinity Reagents Against the Human Proteome (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310 Trans NIH Research Support.
- This funding opportunity was created on Feb 12, 2014 and posted on Feb 12, 2014.
- Applicants must submit their applications by Apr 25, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $6,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Faith based or Community based Organizations Eligibility is limited to cooperative agreement awards that were funded through RFA RM 10 018 Technology Development for New Affinity Reagents Against the Human Proteome (U54). Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This NIH funding opportunity, RFA-RM-14-002, is a limited-competition renewal solicitation for projects focused on technology development to create new affinity reagents against the human proteome. It sits within the NIH Common Fund Protein Capture Reagents Program (PCRP), which is a broader effort aimed at building, over time, a widely usable community resource of high-quality, renewable affinity reagents for essentially all human proteins. The central idea behind the PCRP is to strengthen the national research toolkit by enabling more consistent, reproducible, and broadly accessible protein detection and capture methods, which in turn supports many downstream areas of biomedical research where reliable protein-binding reagents are essential.
The mechanism used is a U01 cooperative agreement, meaning NIH anticipates substantial programmatic involvement during the project period rather than operating strictly as a hands-off grant. In practical terms, cooperative agreements are typically used when a program requires coordination across awardees, active stewardship toward shared program goals, and frequent interaction with NIH staff to align deliverables, data standards, milestones, or resource-sharing practices. The FOA is described as a component of the PCRP and is specifically intended to fund renewal applications, not brand-new entrants, for awards originally made under an earlier solicitation, RFA-RM-10-018, titled "Technology Development for New Affinity Reagents Against the Human Proteome (U54)." In other words, this is a continuation pathway for existing NIH-funded teams from that earlier cohort to extend and further mature their technologies under this renewed competition.
Eligibility is tightly restricted. Only cooperative agreement awards that were funded through RFA-RM-10-018 are eligible to apply for renewal under this FOA. While the general eligibility field notes that "Other Eligible Applicants" can include faith-based or community-based organizations, that statement is effectively subordinate to the limited-competition requirement: applicants must be among the specific prior awardees to qualify. The FOA also explicitly excludes non-U.S. entities: foreign institutions are not eligible, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined in NIH policy) are not allowed. This makes the competition domestic-only and cohort-restricted, reinforcing that the purpose is to renew and advance work already being performed within the established PCRP framework.
From a funding standpoint, the opportunity is part of the NIH Trans-NIH Research Support CFDA listing (93.310) and is categorized under Health. There is no cost-sharing or matching requirement, so applicants are not expected to provide non-federal matching funds as a condition of award. The estimated total funding amount listed is $6,000,000, and the award ceiling is $2,000,000, indicating NIH expected to make multiple awards or support multiple projects under the total allocation, with individual project budgets capped at that ceiling. Because it is a renewal-focused cooperative agreement, the budget and scope would typically be judged in relation to prior progress, continued feasibility, and the value of additional development toward program-level goals.
Key administrative dates indicate the FOA was posted and created on February 12, 2014, with an original and current closing date of April 25, 2014, and an archive date of May 26, 2014. Those dates establish that this was a time-limited renewal round meant to keep momentum for PCRP technology development and to select which of the previously funded efforts would continue forward under the renewed U01 structure.
Overall, the opportunity can be summarized as NIH Common Fund support for continuing, coordinated technology development that advances the production of renewable, high-quality affinity reagents targeting the human proteome, with an emphasis on building a broadly useful public resource. The limited competition, cooperative agreement format, and explicit linkage to the prior RFA-RM-10-018 awards collectively signal that NIH was prioritizing continuity, comparability across projects, and programmatic coordination to accelerate progress toward a comprehensive reagent resource for human proteins.
Frequently Asked Questions (FAQs)
What is the funding opportunity number for this NIH grant?
The funding opportunity number is RFA-RM-14-002.
What is the main goal of RFA-RM-14-002?
This opportunity supports technology development to create new affinity reagents against the human proteome, as part of a broader NIH effort to build a widely usable community resource of high-quality, renewable affinity reagents for essentially all human proteins.
Which NIH program is this FOA part of?
It is part of the NIH Common Fund Protein Capture Reagents Program (PCRP).
What is the purpose of the Protein Capture Reagents Program (PCRP)?
The PCRP aims to strengthen the national research toolkit by enabling more consistent, reproducible, and broadly accessible protein detection and capture methods. Over time, it is intended to produce a broadly useful public resource of renewable, high-quality affinity reagents targeting essentially all human proteins.
What type of award mechanism does this FOA use?
The mechanism is a U01 cooperative agreement.
What does it mean that this is a U01 cooperative agreement?
A U01 cooperative agreement indicates NIH anticipates substantial programmatic involvement during the project period. This typically includes coordination across awardees, frequent interaction with NIH staff, and alignment around shared program goals such as deliverables, milestones, data standards, and resource-sharing practices.
Is this opportunity open to new applicants who were not previously funded under the PCRP?
No. This is a limited-competition renewal solicitation intended for renewal applications only, not for brand-new entrants.
Which prior awards are eligible to apply for this renewal?
Only cooperative agreement awards that were funded through the earlier solicitation RFA-RM-10-018 (titled "Technology Development for New Affinity Reagents Against the Human Proteome (U54)") are eligible to apply for renewal under this FOA.
Is eligibility restricted even if an organization would otherwise be an eligible applicant type?
Yes. Although general eligibility language mentions that "Other Eligible Applicants" can include faith-based or community-based organizations, the limited-competition requirement controls eligibility. Applicants must be among the specific prior awardees funded under RFA-RM-10-018.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible under this FOA.
Can a U.S. organization apply if it proposes a non-domestic component?
No. Non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this FOA?
No. The FOA states that foreign components (as defined in NIH policy) are not allowed.
Is this funding opportunity domestic-only?
Yes. Eligibility exclusions make the competition domestic-only, in addition to being limited to a specific cohort of prior awardees.
Does this opportunity require cost sharing or matching funds?
No. There is no cost-sharing or matching requirement.
What is the estimated total funding amount for this FOA?
The estimated total funding amount is $6,000,000.
What is the maximum award amount (award ceiling) per project?
The award ceiling is $2,000,000.
What does the combination of total funding and award ceiling suggest about the number of awards?
With an estimated total of $6,000,000 and an award ceiling of $2,000,000, NIH likely anticipated making multiple awards or supporting multiple projects under the total allocation, with each individual project capped at the ceiling.
How would budget and scope typically be evaluated for a renewal under this FOA?
Because this is a renewal-focused cooperative agreement, budget and scope would typically be considered in relation to prior progress, continued feasibility, and the value of additional development toward PCRP program-level goals.
What is the CFDA listing associated with this opportunity?
The CFDA listing is 93.310 (NIH Trans-NIH Research Support).
How is this opportunity categorized?
It is categorized under Health.
When was this FOA posted/created?
It was posted and created on February 12, 2014.
What was the closing date for applications?
The original and current closing date listed is April 25, 2014.
When was this FOA archived?
The archive date is May 26, 2014.
What does it mean that this was a time-limited renewal round?
The posted, closing, and archive dates indicate this was a specific, time-bound renewal round intended to continue momentum in PCRP technology development and decide which previously funded efforts would continue under the renewed U01 structure.
What is the broader outcome NIH is trying to achieve through this FOA?
The broader outcome is to accelerate progress toward a comprehensive, broadly useful resource of renewable, high-quality affinity reagents for human proteins, supported through coordinated, continuation-focused technology development within the PCRP framework.
Why does the FOA emphasize continuity and coordination?
The limited competition (restricted to prior awardees), the cooperative agreement structure (with substantial NIH involvement), and the explicit linkage to RFA-RM-10-018 collectively indicate NIH was prioritizing continuity, comparability across projects, and programmatic coordination to advance shared program goals.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization
Previous opportunity: Supporting the University of the West Indies to Deliver and Institutionalize Leadership and Management Training for Health Professionals in Eleven Caribbean Partnership Framework Countries, under the Presidents Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 14 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 14 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| NEI Collaborative Clinical Vision Research Project Grant (U10) Apply for PAR 14 096 Funding Number: PAR 14 096 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Vision Research Resouce Center Grant (UG1) Apply for PAR 14 097 Funding Number: PAR 14 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Vision Research Chairmans Grant (UG1) Apply for PAR 14 098 Funding Number: PAR 14 098 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Vision Research Clinical Center Grant (UG1) Apply for PAR 14 099 Funding Number: PAR 14 099 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Clinical Vision Research Coordinating Center Grant (UG1) Apply for PAR 14 100 Funding Number: PAR 14 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Reaching Practicing MCH Professionals in Underserved Areas Through Education and Training Program Apply for HRSA 14 074 Funding Number: HRSA 14 074 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 14 104 Funding Number: HRSA 14 104 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| PPHF 2014 Access to Recovery (PPHF 2014) Apply for TI 14 004 Funding Number: TI 14 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $3,000,000 |
| Innovative Technologies and Assays in Support of HIV Cure Research (ITAS Cure) (R43/R44) Apply for PA 14 101 Funding Number: PA 14 101 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies and Assays in Support of HIV Cure Research (ITAS Cure) (R41/R42) Apply for PA 14 102 Funding Number: PA 14 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Healthy Start Initiative Eliminating Disparities in Perinatal Health (Level 2 Enhanced Services Healthy Start) Apply for HRSA 14 120 Funding Number: HRSA 14 120 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,200,000 |
| Healthy Start Initiative Eliminating Disparities in Perinatal Health (Level 1 Community based Healthy Start) Apply for HRSA 14 121 Funding Number: HRSA 14 121 Agency: Health Resources and Services Administration Category: Health Funding Amount: $750,000 |
| Healthy Start Initiative Eliminating Disparities in Perinatal Health (Level 3 Leadership and Mentoring Healthy Start) Apply for HRSA 14 122 Funding Number: HRSA 14 122 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,000,000 |
| Miner Safety and Health Training Program Western United States (U60) Apply for RFA OH 14 004 Funding Number: RFA OH 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Minority Serving Institutions (MSIs) Partnerships with Community Based Organizations (CBOs). (Short Title MSI/CBO). Apply for SP 14 005 Funding Number: SP 14 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Public Health Surveillance of Deep Vein Thrombosis and Pulmonary Embolism CDC RFA DD11 1109 Apply for CDC RFA DD14 1407 Funding Number: CDC RFA DD14 1407 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| USAID Jordan Communication, Advocacy and Policy (J CAP) Activity Apply for RFA 278 14 00004 Funding Number: RFA 278 14 00004 Agency: Agency for International Development Category: Health Funding Amount: $30,000,000 |
| Innovation for HIV Vaccine Discovery (R01) Apply for RFA AI 14 006 Funding Number: RFA AI 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| APHL CDC Partnership for Quality Lab Practice Apply for CDC RFA HM10 100105CONT14 Funding Number: CDC RFA HM10 100105CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR) (R43/R44) Apply for RFA EB 14 001 Funding Number: RFA EB 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 14 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.